NCT07152587 (PANDA-SCAP) is a Phase 2, PHASE3 clinical trial of Low dose steroids in Severe Community-acquired Pneumonia (sCAP), sponsored by Qingyuan Zhan.

Who is sponsoring NCT07152587?

NCT07152587 is sponsored by Qingyuan Zhan.

What drugs are being tested in NCT07152587?

Interventions in NCT07152587: Low dose steroids, Moderate dose steroids, Saline (0.9% NaCl).

What condition does NCT07152587 study?

NCT07152587 studies Severe Community-acquired Pneumonia (sCAP).

Is NCT07152587 still recruiting?

NCT07152587 is currently not yet recruiting. Last updated 3 September 2025.

Last reviewed 2025-09-03 · How we verify

NCT07152587: PANDA-SCAP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized Adaptive Platform Trial of Pathogen-Directed Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal)

Not yet recruiting Phase 2, PHASE3 Last updated 3 September 2025

What this trial tests

Phase 2, PHASE3 trial testing Low dose steroids in Severe Community-acquired Pneumonia (sCAP) in 1,500 participants. Not yet recruiting.

Timeline

8 September 2025

Primary endpoint
31 December 2035

31 December 2035

Quick facts

Lead sponsor	Qingyuan Zhan
Phase	Phase 2, PHASE3
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	1,500
Start date	8 September 2025
Primary completion	31 December 2035
Estimated completion	31 December 2035

Drugs / interventions tested

Low dose steroids — full drug profile →
Moderate dose steroids — full drug profile →
Saline (0.9% NaCl) — full drug profile →

Conditions studied

Severe Community-acquired Pneumonia (sCAP) — all drugs for Severe Community-acquired Pneumonia (sCAP) →

Sponsor

Qingyuan Zhan — full company profile →

Who can join

18 and older, any sex, with Severe Community-acquired Pneumonia (sCAP). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Severe community-acquired pneumonia (sCAP) has a high mortality rate of 25-50%. Excessive host inflammatory responses contribute to poor outcomes. Corticosteroid therapy may provide benefit; however, the optimal dosage remains unclear, and it is uncertain whether all etiologies (e.g., Pneumocystis jirovecii, adenovirus, influenza) of sCAP can benefit equally. This study will first establish a comprehensive trial platform based on a prospective sCAP cohort, embedding a randomized, multifactorial, adaptive platform trial (APT). The response-adaptive design will increase the likelihood of patients being assigned to more effective treatment arms, while Bayesian statistical modeling will dynamically assess the efficacy of interventions, allowing early achievement of study endpoints. At the starting stage, two pathogen-specific APTs will be conducted, focusing on adenovirus- and pneumocystis Jirovecii-induced sCAP. Patients admitted to the ICU with confirmed diagnoses of adenovirus or pneumocystis Jirovecii-associated sCAP will be randomized into a control group or one of two corticosteroid dosage groups. The primary endpoint will be 28-day all-cause mortality. Completion of these APTs will provide a theoretical basis for novel anti-inflammatory strategies in sCAP. Moreover, this platform will serve as an essential research infrastructure for the efficient evaluation of new therapeutic options in the event of emerging or re-emerging respiratory pathogens causing sCAP in the future.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Qingyuan Zhan trials

Trials by the same sponsor.

NCT07357935 — Early Inflammatory-Immune Stratification and Precision Glucocorticoid Intervention in Acute Respiratory Failure Induced · Phase 1, PHASE2 · not yet recruiting
NCT07152600 — Adaptive RCT of Corticosteroids for Severe Adenovirus Pneumonia in Adults · Phase 3 · not yet recruiting
NCT07352865 — Adaptive RCT of Corticosteroids for Severe Chlamydia Psittaci Pneumonia in Adults · Phase 3 · not yet recruiting
NCT07351500 — Adaptive RCT of Corticosteroids for Severe Influenza Pneumonia in Adults · Phase 3 · not yet recruiting
NCT07152613 — Corticosteroids for PJP in Non-HIV Immunocompromised Adults · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07152587 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Qingyuan Zhan
Last refreshed: 3 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07152587.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing